Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 4/20 | 0.51 |
| ▸ | BTK | Q06187 | 3/20 | 0.51 |
| ▸ | KDR | P35968 | 3/20 | 0.49 |
| ▸ | LCK | P06239 | 3/20 | 0.49 |
| ▸ | SRC | P12931 | 2/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 10/20 | 0.48 |
| ▸ | CSF1R | P07333 | 2/20 | 0.48 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.45 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.45 |
| ▸ | ITK | Q08881 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4490254 | 0.93 | KDR (0.50) | JAK3BTKKDRLCKSRC | |
| SCHEMBL4491969 | 0.92 | LCK (0.49) | JAK3BTKKDRLCKSRC | |
| SCHEMBL4509912 | 0.92 | LCK (0.55) | JAK3BTKKDRLCKSRC | |
| SCHEMBL4497860 | 0.92 | JAK3 (0.52) | JAK3BTKKDRLCKSRC | |
| SCHEMBL4495272 | 0.90 | CSF1R (0.53) | JAK3BTKKDRLCKSRC | |
| SCHEMBL4487875 | 0.89 | JAK3 (0.48) | JAK3BTKKDRLCKSRC | |
| SCHEMBL4492838 | 0.88 | JAK3 (0.54) | JAK3BTKLCKSRCEGFR | |
| SCHEMBL4488905 | 0.88 | EGFR (0.48) | JAK3BTKKDRLCKSRC | |
| SCHEMBL4496785 | 0.88 | KDR (0.52) | JAK3BTKKDRLCKSRC | |
| SCHEMBL4493427 | 0.87 | CSF1R (0.47) | JAK3BTKKDRLCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648464-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC. (US) | 2006-04-26 | — | — | EP | claimed |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | claimed |
| WO-2005009443-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES | AMGEN INC. (US) | 2005-02-03 | — | — | WO | claimed |
| US-7504396-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | JAK3 900/4885BTK 1420/4885KDR 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.